ArticleClinical and experimental nephrology2026
Interstitial palladin expression is associated with increased risk of end-stage kidney disease and death in patients with biopsy-proven diabetic kidney disease.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundKidney fibrosis is a common mechanism of progressive kidney diseases including diabetic kidney disease (DKD). We have revealed that palladin, an actin-associated protein, drives kidney fibrosis through actin dynamics. However, it has not been elucidated whether palladin is related to the pathogenesis of DKD. In this study, we investigated whether palladin is associated with kidney dysfunction, fibrosis, and prognosis in DKD.
methodsWe conducted a retrospective cohort study of Japanese patients diagnosed with DKD by kidney biopsy between 2000 and 2020. Palladin expression was quantified as the percentage of positive area on immunohistochemistry and log2-transformed (log2 palladin). We assessed its correlation with baseline clinical characteristics and pathological findings. Event-free survival for the initiation of renal replacement therapy (RRT) or all-cause death was analyzed by Kaplan-Meier analysis and Cox proportional hazards regression.
resultsA total of 38 patients were enrolled with a mean age of 57.4 years (10 women). Median follow-up was 2.6 years (range 0.01-19.9), during which 12 patients experienced the composite outcome. On immunohistochemistry, palladin is expressed in myofibroblasts in kidneys from patients with DKD. Log2 palladin was independently associated with lower baseline eGFR (B = - 12.3 mL/min/1.73 m
conclusionInterstitial palladin expression may serve as a histopathological prognostic marker in patients with DKD.
Indexed as
Identifiers
41886153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.